PathAI Launches AIM-MASH on AISight IMS for Enhanced MASH Assessments
TL;DR
PathAI's AIM-MASH on AISight increases reproducibility and scalability for pathologists, providing an advantage in making high-quality, reproducible MASH assessments.
AIM-MASH uses AI-based measurement tools to support the analysis of MASH CRN MASLD activity score component grades and fibrosis staging.
AIM-MASH on AISight aims to make the world a better place by providing digital and AI tools to assist pathologists in making precise and reproducible assessments at scale.
AIM-MASH provides advanced AI-based measurement to support the analysis of MASH CRN MASLD activity score component grades and fibrosis staging.
Found this article helpful?
Share it with your network and spread the knowledge!
PathAI, a leader in artificial intelligence and digital pathology solutions, has launched its new AIM-MASH product on the AISight Image Management System (IMS). This AI-based measurement tool aims to enhance the analysis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and fibrosis staging in liver biopsies. The launch is expected to address a critical gap in pathology labs by providing a standardized and reproducible system for assessing MASH (Metabolic Dysfunction-Associated Steatohepatitis), a condition projected to affect 27 million people in the US by 2030.
The AIM-MASH tools have already been utilized in over 20 presentations and publications, demonstrating their effectiveness in clinical trials. By integrating these tools into the AISight IMS, PathAI aims to streamline the connection between trial and laboratory settings. The tools have undergone rigorous multi-site validation, proving to be highly reliable and effective in guiding pathologists through MASH assessments with high specificity and sensitivity.
Key features of AIM-MASH include highly sensitive and specific reviews, repeatable and reproducible assessments, increased scoring confidence, and global collaboration capabilities. These features allow pathologists to perform accurate first reads comparable to those of expert pathologists, thereby enhancing their final assessments.
A recent case study by PathAI Diagnostics highlighted the practical application of AI in MASH assessments, showcasing the synergy between traditional pathology and AI. This combination enables more precise evaluation of critical histologic features such as steatosis, lobular inflammation, and fibrosis.
Andy Beck, MD, PhD, CEO of PathAI, emphasized the significance of this launch, stating, "This product is a game-changer for drug development, as it supports pathologists in making high-quality, reproducible MASH assessments." Dr. Arun J Sanyal, co-investigator of the AIM-MASH validation study, added that the data supports the use of AIM-MASH in resolving accuracy and precision gaps in MASH assessments.
The introduction of AIM-MASH on the AISight IMS platform broadens the set of tools available to pathologists, helping them make consistent and accurate assessments. This development is poised to empower pathology labs worldwide by enhancing diagnostic accuracy and operational efficiency, ultimately improving patient outcomes.
Curated from News Direct
